Cargando…

Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies

Naringenin (NRG) is a flavonoid and has been reported as an anti-osteoporotic agent. However, poor bioavailability may limit the anti-osteoporotic potential of the drug. The purpose of the study was to compare the anti-osteoporotic activity of naringenin nanosuspension (NRG-NS) with the NRG and stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gera, Sonia, Sampathi, Sunitha, Maddukuri, Sravya, Dodoala, Sujatha, Junnuthula, Vijayabhaskarreddy, Dyawanapelly, Sathish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323949/
https://www.ncbi.nlm.nih.gov/pubmed/35890343
http://dx.doi.org/10.3390/pharmaceutics14071449
_version_ 1784756684462227456
author Gera, Sonia
Sampathi, Sunitha
Maddukuri, Sravya
Dodoala, Sujatha
Junnuthula, Vijayabhaskarreddy
Dyawanapelly, Sathish
author_facet Gera, Sonia
Sampathi, Sunitha
Maddukuri, Sravya
Dodoala, Sujatha
Junnuthula, Vijayabhaskarreddy
Dyawanapelly, Sathish
author_sort Gera, Sonia
collection PubMed
description Naringenin (NRG) is a flavonoid and has been reported as an anti-osteoporotic agent. However, poor bioavailability may limit the anti-osteoporotic potential of the drug. The purpose of the study was to compare the anti-osteoporotic activity of naringenin nanosuspension (NRG-NS) with the NRG and standard therapeutic drug, raloxifene hydrochloride (RLX). Here, NRG-NS showed anti-osteoporotic activity in MG-63 cells by upregulating the osteocalcin levels. The in vivo anti-osteoporotic activity of NRG-NS was further investigated in an osteoporotic rat model to mimic the post-menopausal condition. The animals were randomized and separated into six groups. The animals were treated with RLX (p.o., 5.4 mg/kg), NRG (p.o., 20 mg/kg), NRG-NS (p.o., 20 mg/kg), and blank-NS for 60 days after completion of a 30-day post-surgery period and compared with control and ovariectomized (OVX) groups. After the treatment, body and uterine weights, biochemical estimation in serum (calcium, phosphorus, acid phosphatase, alkaline phosphatase, osteocalcin), bone parameters (length, diameter, dry weight, density, ash weight, bone mineral content) and bone microarchitecture by histopathology were determined. The results showed the protective effects of NRG-NS on osteoblast-like MG-63 cells. The biochemical estimations confirmed the normalization of parameters viz., alkaline phosphatase, calcium concentrations, and bone density with a decrease in levels of acid phosphatase and inorganic phosphorus with NRG-NS as compared to plain NRG. The results indicated that the oral administration of NRG-NS could be a potential therapeutic formulation for the treatment of osteoporosis.
format Online
Article
Text
id pubmed-9323949
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93239492022-07-27 Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies Gera, Sonia Sampathi, Sunitha Maddukuri, Sravya Dodoala, Sujatha Junnuthula, Vijayabhaskarreddy Dyawanapelly, Sathish Pharmaceutics Article Naringenin (NRG) is a flavonoid and has been reported as an anti-osteoporotic agent. However, poor bioavailability may limit the anti-osteoporotic potential of the drug. The purpose of the study was to compare the anti-osteoporotic activity of naringenin nanosuspension (NRG-NS) with the NRG and standard therapeutic drug, raloxifene hydrochloride (RLX). Here, NRG-NS showed anti-osteoporotic activity in MG-63 cells by upregulating the osteocalcin levels. The in vivo anti-osteoporotic activity of NRG-NS was further investigated in an osteoporotic rat model to mimic the post-menopausal condition. The animals were randomized and separated into six groups. The animals were treated with RLX (p.o., 5.4 mg/kg), NRG (p.o., 20 mg/kg), NRG-NS (p.o., 20 mg/kg), and blank-NS for 60 days after completion of a 30-day post-surgery period and compared with control and ovariectomized (OVX) groups. After the treatment, body and uterine weights, biochemical estimation in serum (calcium, phosphorus, acid phosphatase, alkaline phosphatase, osteocalcin), bone parameters (length, diameter, dry weight, density, ash weight, bone mineral content) and bone microarchitecture by histopathology were determined. The results showed the protective effects of NRG-NS on osteoblast-like MG-63 cells. The biochemical estimations confirmed the normalization of parameters viz., alkaline phosphatase, calcium concentrations, and bone density with a decrease in levels of acid phosphatase and inorganic phosphorus with NRG-NS as compared to plain NRG. The results indicated that the oral administration of NRG-NS could be a potential therapeutic formulation for the treatment of osteoporosis. MDPI 2022-07-11 /pmc/articles/PMC9323949/ /pubmed/35890343 http://dx.doi.org/10.3390/pharmaceutics14071449 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gera, Sonia
Sampathi, Sunitha
Maddukuri, Sravya
Dodoala, Sujatha
Junnuthula, Vijayabhaskarreddy
Dyawanapelly, Sathish
Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies
title Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies
title_full Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies
title_fullStr Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies
title_full_unstemmed Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies
title_short Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies
title_sort therapeutic potential of naringenin nanosuspension: in vitro and in vivo anti-osteoporotic studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323949/
https://www.ncbi.nlm.nih.gov/pubmed/35890343
http://dx.doi.org/10.3390/pharmaceutics14071449
work_keys_str_mv AT gerasonia therapeuticpotentialofnaringeninnanosuspensioninvitroandinvivoantiosteoporoticstudies
AT sampathisunitha therapeuticpotentialofnaringeninnanosuspensioninvitroandinvivoantiosteoporoticstudies
AT maddukurisravya therapeuticpotentialofnaringeninnanosuspensioninvitroandinvivoantiosteoporoticstudies
AT dodoalasujatha therapeuticpotentialofnaringeninnanosuspensioninvitroandinvivoantiosteoporoticstudies
AT junnuthulavijayabhaskarreddy therapeuticpotentialofnaringeninnanosuspensioninvitroandinvivoantiosteoporoticstudies
AT dyawanapellysathish therapeuticpotentialofnaringeninnanosuspensioninvitroandinvivoantiosteoporoticstudies